The FDA Adds a New Warning Linked to Johnson & Johnson COVID-19 Vaccine
Johnson & Johnson, in a discussion with federal agencies, confirmed that its COVID-19 vaccine is linked to Guillain-Barré syndrome (GBS), a rare neurological disorder. Following this confirmation, on July 12 The Food and Drug Administration (FDA) announced that it will add a warning label to Johnson & Johnson’s COVID-19 vaccine via a fact sheet for providers and patients!
Key among the findings within the fact sheet were alarming data which showed that the chances of developing GBS without the J&J vaccine are low. However, recipients of the J&J vaccine are three to five times more likely to develop the neurological disorder. The federal monitoring system has identified 100 suspected cases of Guillain-Barre among those who received Johnson & Johnson’s one-dose shot.
The FDA provided a preliminary report which showed that 95% of the cases containing the rare neurological disorder associated with the J&J covid vaccine were considered severe and required hospitalization of those affected.
District Judge Christina Snyder ruled that the policy illegally discriminated against federal officers by singling them out while excluding state and local law enforcement.